Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 28, 2026
Larimar Therapeutics, Inc. (LRMR)
A forensic read on Larimar Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Distress
Financial health
-46.1
Altman Z-score
Watch
Earnings quality
2
Forensic signals
-134.1%
ROE
$380M
Market cap
Larimar Therapeutics, Inc. earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is -46.1, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-50%Return on invested capital.Return on invested capital is -50% and rising from -123% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+85.6%/yrShare-count dilution.Diluted share count changed +257% over the last 3 years to FY2024 (+85.6%/yr). The count is GROWING — existing holders are being diluted. That's ~85.6% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2021 has been diluted ~257%.
Key fundamentals
Debt / Equity0.19x
Free Cash Flow$-113.3M
Return on Equity-212.2%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Larimar Therapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about LRMR's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown